SEC Form 4

FORM 4		UNITED STATES SECURITIES AND EXCHANGE COMMISSION	
		Washington, D.C. 20549	OMB APPROV
C Sect	Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See	STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP	OMB Number: 3 Estimated average burden hours per response:
	Instruction 1(b).	Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934	
		or Section 30(h) of the Investment Company Act of 1940	
	1. Name and Address of Reporting Person*	2. Issuer Name and Ticker or Trading Symbol VEPTEX DHAPMACELITICALS INC / MA (Check all applic)	Reporting Person(s) to Issuer

		Table I - Non-D	erivative Securities Acquired, Disposed of, or Benefi	cially C	Dwned				
(City)	(State)	(Zip)							
CAMBRIDGE MA 02139		02139	_		Form filed by More that Person	an One Reporting			
(Street)		02120		X	,				
130 WAVERLY STREET			4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Indiv Line)	6. Individual or Joint/Group Filing (Check Applica				
				1					
C/O VERTEX P INCORPORATE	_	UTICALS	3. Date of Earliest Transaction (Month/Day/Year) 02/04/2010	CEO					
(Last)	(First)	(Middle)		X	Officer (give title below)	Other (specify below)			
			[VRTX]		Director	10% Owner			
Emmens Mat	1 0	F CISUL	VERTEX PHARMACEUTICALS INC / MA	(Check	(Check all applicable)				

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)			4. Securities A Disposed Of (I			5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership
			Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(Instr. 4)
Common Stock	02/04/2010		Α		47,201(1)	Α	\$0.01	182,205	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. 3. Transaction Date 3. Deemed 4. Transaction Code (Instr. 0 Conversion or Exercise Price of Derivative Security 0.00000000000000000000000000000000000		Derivative		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		
			Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		Transaction(s) (Instr. 4)		
Stock Options	\$39.05	02/04/2010	A		354,000 ⁽²⁾		05/04/2010	02/03/2020	Common Stock	354,000	\$0	354,000	D	

Explanation of Responses:

1. Stock grant under 2006 Stock and Option Plan, vesting on 2/4/2014, subject to 50% acceleration upon receiving U.S. marketing approval for telaprevir; and to 50% acceleration upon either (a) reaching specified telaprevir sales levels during 18 months following its U.S. launch or (b) launch of any additional drug beyond telaprevir prior to December 31, 2012.

2. Stock option under 2006 Stock and Option Plan, vesting in 16 equal quarterly installments over four years.

Remarks:

Kenneth S. Boger, Attorney-In-Fact

02/08/2010

APPROVAL

3235-0287

0.5

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.